MSMisuzu Sato

Misuzu Sato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Misuzu Sato has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Hideo Yasunaga

    Department of Clinical Epidemiology and Health Economics, School of Public Health The University of Tokyo Tokyo Japan

    3 shared publications
  • Sachiko Ono

    Department of Eat‐loss Medicine, Graduate School of Medicine The University of Tokyo Tokyo Japan

    3 shared publications
  • Hayato Yamana

    Data Science Center Jichi Medical University Shimotsuke Tochigi Japan

    2 shared publications
  • Miho Ishimaru

    The Institute of Education Tokyo Medical and Dental University Bunkyo City Tokyo Japan

    2 shared publications
  • Miho Ishimaru

    Center for Data Science and Artificial Intelligence Education, Institute of Science Tokyo, Tokyo, Japan

    2 shared publications
  • Sachiko Ono

    Department of Eat-loss Medicine, Graduate School of Medicine, The University of Tokyo

    2 shared publications

Latest Publications

  • Multiple Tobacco Product Use and Dental Pain: A Cross-sectional Study

    by T. Yamamoto, H. Abbas, M. Sato, M. Iwasaki, T. Tabuchi

    Introduction: Although individual tobacco products, including new tobacco products, have been associated with adverse oral health outcomes, few studies have examined the association between multiple tobacco product (MTP) use and dental pain as an indicator of current oral health status. Methods: We conducted a cross-sectional study using data from a nationwide internet survey in Japan. The 2023 survey included the outcome variable, current tobacco product use, and most covariates; however, it did not include the number of remaining teeth, an oral health–related covariate relevant to interpreting dental pain. Therefore, we included participants who responded to the 2023 survey and for whom information on remaining teeth was available from the 2022 survey. Current tobacco product use was assessed for 6 product types: cigarettes, heated tobacco products, electronic cigarettes, cigars, pipe/water pipes, and smokeless tobacco. Participants were categorized as having no current product use, single-product use, or MTP use. The outcome was self-reported dental pain within the past week. Covariates were sex, age, education, household income, living alone, marital status, drinking, self-rated health, psychological distress, number of remaining teeth, and daily toothbrushing. We used multivariable modified Poisson regression to estimate adjusted prevalence ratios (aPRs) and 95% CIs. Results: We analyzed 19,703 participants; the mean age was 50.2 y (SD, 16.9) and 10,165 (51.6%) were men. Overall, 2518 participants (12.8%) reported dental pain within the past week, 2463 (12.5%) used a single tobacco product, and 1040 (5.3%) used MTPs. After adjustment for all covariates, MTP use was associated with a higher prevalence of dental pain (single-product use: aPR, 1.03 [95% CI, 0.92–1.15]; MTP use: aPR, 1.39 [95% CI, 1.25–1.54]). Conclusions: MTP use was associated with dental pain. Longitudinal studies are needed to clarify the temporal and causal relationships between MTP use and oral health. Knowledge Transfer Statement: The findings of this study suggest that collaboration between policy makers in dental and oral health and those in tobacco control may be important for addressing oral health disparities between tobacco users and nonusers.

  • Open Access

    Administrative Claims Databases in Dentistry: Current Applications, Methodological Trends, and Evidence Gaps: A Global Scoping Review of Dataset Characteristics

    by Misuzu Sato, Sachiko Ono, Miho Ishimaru, Yusuke Ida

    Objectives: Administrative claims databases are increasingly used in dental research. However, inconsistencies in data coverage and the lack of a global overview remain as challenges. This review aimed to summarize worldwide studies using dental administrative claims databases, focusing on research questions, methodologies, and findings to identify key trends and knowledge gaps. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses extension for Scoping Reviews (PRISMA‐ScR), we conducted a scoping review of studies using dental administrative claims data published between January 2010 and December 2025. We structured the review question using the Population‐Concept‐Context framework. The original search through April 2022, as registered in PROSPERO, was updated in April 2026 using the same search strategy and eligibility criteria. We searched PubMed, Ovid MEDLINE, Ichushi‐Web, CiNii, Scopus, and Web of Science databases. Two reviewers independently screened the records, and disagreements were resolved by consensus. Cohort and case–control studies were critically appraised using the Newcastle–Ottawa Scale (NOS) to characterize the methodological quality of the mapped literature. Results: Following screening, 472 studies met the eligibility criteria. Most studies originated from the United States and Taiwan, indicating marked geographical concentration; the updated search added Switzerland and New Zealand. Research topics included treatment effectiveness, the epidemiology of rare conditions, healthcare utilization, and policy evaluation. Common limitations were insufficient clinical detail, variable data quality, and limited generalizability. Conclusions: This review highlights the expanding use of administrative claims databases in dental research and their inherent limitations. Future research should prioritize validating claims‐based diagnosis and procedure codes and linking claims data with clinical records.

  • Open Access

    Differences in health care expenditure due to the comorbidity status of periodontal disease and diabetes mellitus

    by Anna Kinugawa, Kenji Takeuchi, Yudai Tamada, Taro Kusama, Misuzu Sato, Megumi Maeda, Fumiko Murata, Ken Osaka, Haruhisa Fukuda

    Background: To investigate the differences in health care expenditure (HCE) due to the comorbidity status of periodontal disease (PD) and diabetes mellitus (DM).Methods: This cohort study used health care claims and oral health screening data to identify participants with PD or DM and followed them for 1 year to assess their HCE. PD and DM were determined based on PD screening and medical claims data, respectively. The study participants were divided into four groups: participants without PD and DM (PD−/DM−), participants with PD and without DM (PD+/DM−), participants without PD and with DM (PD−/DM+), and participants with PD and DM (PD+/DM+). Covariates included age, sex, smoking status, and Charlson Comorbidity Index (CCI) score. A generalized linear model (GLM) with a gamma distribution and log link function was used to examine the association between comorbidity and annual HCE, and a two‐part model was used to assess the differences in annual HCE.Results: In total, 790 participants (mean age: 63.1, 30.3% male) were included. Compared with the PD−/DM− group, the relative cost ratio (RCR) for the PD+/DM+, PD−/DM+, PD+/DM− groups were 1.31 (95% confidence interval [CI]: 1.06–1.62), 1.27 (95% CI: 0.99–1.64), 1.01 (95% CI: 0.89–1.14) times higher, respectively. The adjusted mean annual HCE for the PD+/DM+, PD−/DM+, PD+/DM− groups were ¥59,328 (95% CI: 14,171–104,484), ¥50,228 (95% CI: −15,801–116,256), ¥‐2,162 (95% CI: −24,598–20,274) higher than the PD−/DM− group, respectively.Conclusion: This study provides a significant contribution of PD to the increase in HCE, particularly in individuals with DM.Plain Language Summary: The association between periodontal disease (PD) and diabetes mellitus (DM) has commonly been described in previous literature, but the health expenditure incurred when PD and DM coexist is not clear. This study investigates the differences in health care expenditure (HCE) due to the comorbidity status of PD and DM. HCE is calculated from medical, dental, and pharmacy‐dispensing expenditures from the claims data. PD was defined by periodontal pocket scores, and DM was determined based on medical records. Study participants were divided into four groups based on whether they had PD, DM, both, or neither. The results showed that people with both PD and DM had higher HCE compared with those without PD and DM. These findings may suggest the importance of cooperation between medical and dental professionals in the treatment of DM in terms of HCE.

  • Effect of periodontal therapy on glycaemic control in type 2 diabetes

    by Misuzu Sato, Sachiko Ono, Hayato Yamana, Akira Okada, Miho Ishimaru, Yosuke Ono, Masanori Iwasaki, Jun Aida, Hideo Yasunaga

    Aim: This study aimed to elucidate the impact of periodontal therapy on glycaemic control in individuals with type 2 diabetes and various baseline blood glucose levels using a large‐scale claims database from Japan.Materials and Methods: Using the JMDC Claims Database, we identified individuals with type 2 diabetes who underwent health check‐ups in the fiscal years 2018 or 2019 and were followed up until the next year's health check‐up. We conducted a weighted cohort analysis using stabilized inverse probability weights for treatment and censoring to estimate the effect of periodontal therapy on changes in haemoglobin A1c levels within a year. Analysis was done for different baseline haemoglobin A1c categories: 6.5%–6.9%, 7.0%–7.9% and ≥8.0%.Results: Of the 4279 insured persons included in the study, 957 received periodontal therapy. Overall, there was a tendency towards improved glycaemic control among those who received periodontal therapy. Participants with baseline haemoglobin A1c levels of 7.0%–7.9% who received periodontal therapy exhibited significantly better glycaemic control compared with those without dental visits (difference; −0.094 [95% confidence interval: −0.181 to −0.007]).Conclusions: Periodontal therapy may improve glycaemic control in individuals with diabetes, especially in those with haemoglobin A1c levels ≥7.0%.


  • Amoxicillin vs third‐generation cephalosporin for infection prophylaxis after third molar extraction

    by Misuzu Sato, Hayato Yamana, Sachiko Ono, Miho Ishimaru, Hiroki Matsui, Hideo Yasunaga

    Objectives: Although amoxicillin is the first‐line prophylactic drug for impacted mandibular third molar extraction, third‐generation cephalosporins are widely prescribed in Japan. The lack of real‐world evidence may be one reason for this inappropriate use. We evaluated differences in the incidence of surgical site infection between amoxicillin and third‐generation cephalosporins for impacted mandibular third molar extraction.Methods: Using the JMDC Claims Database, we identified dental visits with fully or horizontally impacted mandibular third molar extraction from April 2015 to March 2020. One‐to‐one propensity‐score matching was conducted between amoxicillin and third‐generation cephalosporin groups. The incidence of surgical site infection following extraction was compared in the matched pairs using McNemar's test.Results: We identified 109,266 dental visits, including 39,514 (36.2%) patients who received amoxicillin and 69,752 (63.8%) patients who received third‐generation cephalosporins. In the 39,514 matched pairs, the incidence of surgical site infection was 3.5% (n = 1399) for amoxicillin group and 3.7% (n = 1467) for third‐generation cephalosporin group (p = 0.003).Conclusions: Amoxicillin was associated with a lower incidence of surgical site infection after impacted mandibular third molar extraction compared with third‐generation cephalosporins. This result supports current guidelines and strengthens the importance of disseminating and implementing antimicrobial resistance control in dentistry.